| Ytd | -62.24% | |
| 1y | -76.79% |
| Open | 4.21 | Prev Close | 4.18 | Low | 4.14 | High | 4.55 | Mkt Cap | 13.13M |
| Vol | 51.51K | Avg Vol | 61.45K | EPS | -4.80 | P/E | N/A | Forward P/E | -2.33 |
| Beta | -2.83 | Short Ratio | 3.67 | Inst. Own | 7.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.52 | 200-d Avg | 10.84 | 1yr Est | 8.25 |
FEMY News
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgi
The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shi
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg
Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.06) per share which beat the analyst consensu
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg
Lake Street analyst Benjamin Haynor initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating
-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven t
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility trea
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical perman
Femasys Inc. (NASDAQ: FEMY) ("Femasys" or the "Company"), a leading biomedical innov
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane
-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support f
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announ
Laidlaw & Co. analyst Yale Jen initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating
Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.10) per share which beat the analyst consensu
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane
https://www.nytimes.com/2025/10/16/us/politics/trump-ivf-fertility.html
Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical perman
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane
Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane